AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03492203 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Bridging strategies
Description: The online forum will have illustrations for bridging cognitive abilities and problem solving strategies related to each game to experiences in the real world. An at home workbook will also be used to facilitate active application of skills in various domains (e.g., work, socialization, recreation, household maintenance).
Study NCT03084237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLX02
Description: 8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
Study NCT03084237 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin®
Description: 8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles
Study NCT03084237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m2 will be administered on Day 2, Cycle 1.then be given every 3 weeks on Day 1 of each subsequent cycle
Study NCT03084237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m2 will be administered on Day 2, Cycle 1.then be given every 3 weeks on Day 1 of each subsequent cycle
Study NCT01935115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol anesthesia for ECT
Study NCT01935115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine anesthesia for ECT
Study NCT01926158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumb
Description: Prefilled syringe of 1 mL denosumab solution
Study NCT01926158 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for denosumab)
Study NCT03201991 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Resistance Exercise Program
Description: The resistance exercise program will involve three sets of 10 repetitions of each exercise in levels 1 and 2 every day. Participants will be given instructions to follow.
Study NCT01899911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vital Signs Patch (VSP)
Description: Infrared and red absorbance measurement
Study NCT01466361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine lower dose
Description: lower dose nicotine lozenge
Study NCT01466361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine higher dose
Description: higher dose nicotine lozenge
Study NCT01466361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT03568435 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT04056169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high-dose rosuvastatin
Description: rosuvastatin 20 mg once a day for 6 months
Study NCT04056169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose rosuvastatin plus ezetimibe
Description: ezetimibe/rosuvastatin 10/5 mg once a day for 6 months
Study NCT00392223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin microspheres
Description: Azithromycin microspheres, powder for oral suspension, 2 g a week, in unique administration PO, repeated weekly for 8 weeks and minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
Study NCT00392223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minocycline-placebo capsules
Description: minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
Study NCT00392223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin microspheres-placebo
Description: Minocycline capsules, PO, 100 mg daily for 8 weeks and Azithromycin microspheres-placebo once a week for 8 weeks plus azithromycin placebo.
Study NCT00392223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline capsules,
Description: Capsules, PO, 100 mg daily for 8 weeks.
Study NCT02783911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MTA
Description: Mineral Trioxide Aggregate grey paste
Study NCT02783911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Sulfate
Description: Ferric Sulfate paste
Study NCT00872742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance enhanced behavior therapy (AEBT)
Description: Ten 1-hour sessions over 12 weeks, enhancing awareness of hair-pulling behavior and teaching strategies to deal with hair pulling
Study NCT00872742 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation and supportive therapy (PST)
Description: Ten 1-hour sessions over 12 weeks, teaching the participant about hair pulling and discussing how hair pulling affects those who do it
Study NCT00747214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRx-102
Study NCT00747214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00747214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARD Therapy
Description: DMARD therapy can include methotrexate or other DMARD therapy
Study NCT00747214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DMARD Therapy
Description: DMARD therapy can include methotrexate or other DMARD therapy
Study NCT04155645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8233 subcutaneous injection
Description: Randomized subjects will receive SC dose of AZD8233 (dose 1, dose 2, and dose 3) injection.
Study NCT04155645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomized subjects will receive SC dose of placebo injection.
Study NCT02339688 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional MS rehabilitation
Description: assessment pre and post conventional MS rehabilitation
Study NCT04748978 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysteroscopy
Description: OPPIum and Myolysis
Study NCT02080416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: Nelfinavir will be given 3000 mg orally twice daily on days 1-14 of a 14-day cycle. NFV will be continued in patients tolerating therapy for 4 cycles (8 weeks).
Study NCT03048786 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will receive automated text messages used by SmokefreeTXT. The messages are designed to provide encouragement, support, and information about quitting smoking. Participants will receive 1-5 automated messages per day for 6-8 weeks depending on choice of quit date.
Study NCT03048786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentoring
Description: Participants will receive a modified version of the automated text messages sent to the control arm plus random assignment to a peer mentor. The modified messages include automated conversation starters, designed to stimulate conversation with the peer mentor. The peer mentor will then send personalized, tailored responses. The peer mentor is a former smoker who has completed a training program developed by the investigator team. Participants will receive 1-5 automated messages per day for 6-8 weeks depending on choice of quit date.
Study NCT01933594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: RMD administered over 4 hours via an intravenous (IV) catheter.
Study NCT01933594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Romidepsin
Description: Placebo for RMD administered over 4 hours via an IV catheter.
Study NCT04357795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CequaTM (Cyclosporine 0.09%) ophthalmic solution
Description: One drop CequaTM (Cyclosporine 0.09%) ophthalmic solution in each eye twice daily, approximately 12 hours apart.
Study NCT00815152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: coping skills intervention training
Description: The strategies will include ways to improve problem solving, communication skills, and managing activities.
Study NCT00815152 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: The ususal care at the Preston Robert Tisch Brain Tumor Center
Study NCT00262119 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker Medtronic EnRhythm
Description: Pacemaker specific programming
Study NCT04334369 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Proclear Single Vision Contact Lenses manufactured by CooperVision
Description: FDA approved single vision contact lenses.
Study NCT04334369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proclear Multifocal Contact Lenses manufactured by CooperVision
Description: FDA Approved Multifocal Contact Lenses
Study NCT00833755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
Study NCT00833755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
Study NCT02754739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Pravastatin 40mg once daily for 24 weeks and nutritional education by a nutritionist
Study NCT02664675 — intervention group
Intervention type: PROCEDURE
Intervention: Crown lengthening
Description: After a local anesthesia, gingival tissue is removed around the teeth to extend the length of the crown for aesthetic or prosthetic matter.
Study NCT02664675 — intervention group
Intervention type: PROCEDURE
Intervention: Open Flap Debridement
Description: After local anesthesia, intra-sulcular incisions are done and a flap is released to access to the intra-bony defect.~Granulation tissue is removed and carefully laid aside for further analysis. Interrupted sutures are done to close the flap.
Study NCT03687632 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ST266
Description: 1X ST266 applied in a dose of one drop (30-50 µL) in the study eye for 28 days (112 doses total will be administered).
Study NCT01612663 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pain relief by Acupuncture needle at non-specific site
Study NCT01612663 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture needle
Study NCT01612663 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture needle
Study NCT03468621 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wound closure
Description: Method of wound closure
Study NCT01832766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: dronabinol 10 mg one capsule by mouth at 8:00 a.m.
Study NCT01832766 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: one capsule given by mouth at 8:00 a.m.
Study NCT04331106 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Online Questionnaire
Description: Online Questionnaire via SoSci Survey
Study NCT03356093 — intervention group
Intervention type: OTHER
Intervention: complete questionnaire
Description: Patients were asked to complete a questionnaire at baseline, and week 1, 2, 3, 4, 5 and 6 after starting of radiotherapy.
Study NCT05149339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 2800 I.U. ml oral drops
Description: (Cholecalciferol 2800 I.U. ml) Oral Drops 15 ml. supplied with a dropper.~* Composition:~Each 1 ml (= 28 drops) of oral solution contains: Vitamin D3 (Cholecalciferol) 2800 I.U., (each drop contains 100 IU of vitamin D3).
Study NCT03995563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Continous epidural injection will be done during 10 days. D group will be injected a 0.19% ropivacaine 8mL and dexametasone 1mg every other day during 10 days.~.
Study NCT03995563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Continous epidural injection will be done during 10 days Both group will be injected a 0.19% ropivacaine 8mL every other day during 10 days
Study NCT03995563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Continous epidural injection will be done during 10 days Both group will be injected a 0.19% ropivacaine 8mL every other day during 10 days
Study NCT03297632 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Functional resistance exercise
Description: Functional resistance program designed for older individuals with low muscle mass and muscle strength. The goal is to implement exercises that are possible for the participants to also perform in their home environment, through the use of basic equipment.
Study NCT03297632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional resistance exercise
Description: Functional resistance program designed for older individuals with low muscle mass and muscle strength. The goal is to implement exercises that are possible for the participants to also perform in their home environment, through the use of basic equipment.
Study NCT01114724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant Thoracic Stent Graft with the Captivia Delivery System
Description: All subjects will be implanted with this device
Study NCT01943617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: anti-viral therapy
Study NCT01943617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: anti-viral therapy
Study NCT01943617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin-α
Description: anti-viral and antitherapy
Study NCT00720135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DI-Leu16-IL2 immunocytokine
Description: Given IV
Study NCT00720135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00720135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT00720135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT00720135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00720135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00720135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies
Study NCT00720135 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative studies
Study NCT00864110 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)
Description: one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20 mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG will be injected
Study NCT00864110 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Technetium 99m ethylenedicysteine-deoxyglucose
Description: 99mTc EC-DG injection, single dose, slow IV push over 3-5 minutes, yielding a target activity of 20 mCi (range 20-30 mCi)
Study NCT00864110 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 18 F fluorodeoxyglucose
Description: single injection of 18F FDG (range 10-20 mCi)
Study NCT02404571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDP chemotherapy
Description: gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
Study NCT03495518 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Symptom feedback to Health Care Provider
Description: These children will complete SPARK daily for 5 days in a row, daily symptom reports will be printed and provided in the patient chart. On days 1 and 3, a report describing symptoms that are a lot or extremely bothersome will be emailed to the physician providing direct medical
Study NCT03495518 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: A clinical research associate will visit the participant on days 1 and 5±1 and will obtain SSPedi scores on an iPad. Reports will not be printed or emailed to the physician.
Study NCT03869099 — intervention group
Intervention type: OTHER
Intervention: Pneumonia Case Management Practices
Description: Standard practices of pneumonia case management at three levels of health care; community level, first level care facility and practitioner level, across Pakistan.
Study NCT02703766 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: overfeeding induced weight gain
Study NCT02703766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: overfeeding induced weight gain
Study NCT00963508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Malathion gel 0.5%
Description: Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
Study NCT00963508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin 1% rinse (Nix Crème)
Description: Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head head lice are still present.
Study NCT03571789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vine™
Description: The Vine™ is made of a super-elastic nitinol wire comprises a helix that resides within the CCA lumen and a linear stem that traverses the CCA wall. The helix includes three segments: supporting coils, filter, and leading coils.~The device is available in sizes of 6.0mm - 10.0mm (in 0.5mm intervals) to accommodate individual CCA diameters
Study NCT01222299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bepotastine besilate nasal product - low dose
Description: sterile nasal product
Study NCT01222299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bepotastine besilate nasal product - medium dose
Description: sterile nasal product
Study NCT01222299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bepotastine besilate nasal product - high dose
Description: sterile nasal product
Study NCT01222299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator nasal product
Description: sterile nasal product
Study NCT02530541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHG
Description: Varied application times
Study NCT02530541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHG
Description: Varied application times
Study NCT02754739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Pravastatin)
Description: Pill manufactured to mimic pravastatin 40mg tablet once daily for 24 weeks and nutritional education by a nutritionist
Study NCT02754739 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutritional education only
Description: Only nutritional education by a nutritionist
Study NCT04147520 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Interview
Description: Single (60 min) session discussion of alcohol use and associated experiences.
Study NCT03122132 — intervention group
Intervention type: DRUG
Intervention: ombitasvir/paritaprevir/ritonavir 8 weeks
Description: Spanish cohort with HCV treated in real practice with ombitasvir/paritaprevir/ ritonavir 8 weeks
Study NCT03122132 — intervention group
Intervention type: DRUG
Intervention: dasabuvir 8 weeks
Description: Spanish cohort with HCV treated in real practice with dasabuvir 8 weeks
Study NCT02432508 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser acupuncture (Olympic)
Description: Physiolaser Olympic laser acupuncture device (50mW, 655nm)
Study NCT02432508 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Laser acupuncture (Olympic)
Description: Physiolaser Olympic laser acupuncture device (50mW, 655nm)
Study NCT02432508 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Laser acupuncture (Olympic)
Description: Physiolaser Olympic laser acupuncture device (Low dose of laser energy: 5mW, 655nm)
Study NCT02432508 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser acupuncture (Olympic)
Description: Physiolaser Olympic laser acupuncture device (Low dose of laser energy: 5mW, 655nm)
Study NCT02907307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LactiSal vaginal gel 1%
Description: to be administered daily intravaginally for 6 days
Study NCT02907307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LactiSal vaginal tablet 50mg
Description: to be administered daily intravaginally for 6 days
Study NCT02907307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole vaginal tablet 100mg
Description: to be administered daily intravaginally for 6 days